The Experts below are selected from a list of 4620 Experts worldwide ranked by ideXlab platform
Matti Välimäki - One of the best experts on this subject based on the ideXlab platform.
-
one year follow up of patients with acromegaly treated with fixed or titrated doses of Lanreotide autogel
Clinical Endocrinology, 2004Co-Authors: Ph. Caron, D. R. Cullen, Jochen Schopohl, Mieke Bex, U Feldtrasmussen, A Pico M Alfonso, S Pynka, Karoly Racz, A Tabarin, Matti VälimäkiAbstract:Summary objective Somatostatin analogue treatment is first-line medical therapy for acromegaly. This study compared the efficacy and tolerability of titrated doses of the long-acting somatostatin analogue preparation Lanreotide Autogel® with fixed doses and with Lanreotide prolonged release (PR) 30 mg microparticles. patients Patients entering the initial study had received a diagnosis of active acromegaly within the previous 5 years. design This open, comparative, multicentre study was a 1-year extension of a previous trial during which patients with acromegaly had switched from Lanreotide PR 30 mg microparticles injected intramuscularly every 7, 10 or 14 days, for at least 3 months, to one of three fixed doses of Lanreotide Autogel® (120, 90, or 60 mg every 28 days, respectively). In this extension study, patients continued to receive 60, 90, or 120 mg of Lanreotide Autogel® by deep subcutaneous injection every 28 days for 1 year. Doses could be titrated at entry or after four or eight injections, according to the GH/IGF-I response (dose increased if GH > 2·5 µg/l, or decreased if GH < 1 µg/l with normal IGF-I). measurements Mean ± SEM GH and IGF-I concentrations were analysed and gallbladder echography performed at weeks 0, 16, 32, and 48. Acromegaly symptoms were recorded monthly and tolerance and side-effects were monitored throughout the study. results In total, 130 patients entered this extension phase. After 1 year of treatment with titrated doses of Lanreotide Autogel®, mean GH (2·4 ± 0·2 µg/l) and IGF-I (287 ± 12 µg/l) concentrations were significantly lower than with Lanreotide microparticles (GH, 2·8 ± 0·2 µg/l, P < 0·001; IGF-I, 332 ± 15 µg/l, P < 0·01) or with fixed-dose Lanreotide Autogel® (GH, 3·0 ± 0·2 µg/l, P < 0·001; IGF-I, 310 ± 14 µg/l, P = 0·02). GH hypersecretion was reduced to ≤ 2·5 µg/l in 68% of patients with titrated-dose Lanreotide Autogel® compared with 49% with microparticles (P < 0·001) and 56% with fixed-dose Lanreotide Autogel® (P ≤ 0·005). In the 65 patients who did not require any dose titration, there was no substantial change in serum Lanreotide concentration, GH or IGF-I levels over the 12-month study duration. Acromegaly was effectively controlled (GH ≤ 2·5 µg/l and normalized IGF-I) in significantly more patients (43%) compared with microparticles (32%; P < 0·05). There was a trend for improved control of acromegalic symptoms with dose titration, whereas the incidence of gastrointestinal symptoms and local tolerance was similar with Lanreotide Autogel® and Lanreotide microparticles. Gallbladder echographies showed new lithiasis in 8% of Lanreotide Autogel® patients. conclusion Dose titration of Lanreotide Autogel® improved GH and IGF-I control in patients with acromegaly beyond that achieved using fixed doses of Lanreotide Autogel® or Lanreotide microparticles. Titrated long-term Lanreotide Autogel® treatment is well tolerated.
-
One-year follow-up of patients with acromegaly treated with fixed or titrated doses of Lanreotide Autogel®
Clinical endocrinology, 2004Co-Authors: Ph. Caron, D. R. Cullen, Jochen Schopohl, Mieke Bex, S Pynka, Karoly Racz, A Tabarin, U Feldt-rasmussen, A M Pico Alfonso, Matti VälimäkiAbstract:Summary objective Somatostatin analogue treatment is first-line medical therapy for acromegaly. This study compared the efficacy and tolerability of titrated doses of the long-acting somatostatin analogue preparation Lanreotide Autogel® with fixed doses and with Lanreotide prolonged release (PR) 30 mg microparticles. patients Patients entering the initial study had received a diagnosis of active acromegaly within the previous 5 years. design This open, comparative, multicentre study was a 1-year extension of a previous trial during which patients with acromegaly had switched from Lanreotide PR 30 mg microparticles injected intramuscularly every 7, 10 or 14 days, for at least 3 months, to one of three fixed doses of Lanreotide Autogel® (120, 90, or 60 mg every 28 days, respectively). In this extension study, patients continued to receive 60, 90, or 120 mg of Lanreotide Autogel® by deep subcutaneous injection every 28 days for 1 year. Doses could be titrated at entry or after four or eight injections, according to the GH/IGF-I response (dose increased if GH > 2·5 µg/l, or decreased if GH
-
Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly
The Journal of clinical endocrinology and metabolism, 2002Co-Authors: Ph. Caron, Albert Beckers, D. R. Cullen, M. I. Goth, B. Gutt, Peter Laurberg, Antonio Picó, Matti Välimäki, W. ZgliczynskiAbstract:Lanreotide Autogel is a new long-acting aqueous preparation of Lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to Lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with Lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from Lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg Lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of Lanreotide Autogel, mean Lanreotide levels were similar to those obtained at steady state with Lanreotide 30 mg. During Lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during Lanreotide 30 mg treatment. After 3 injections of Lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of Lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during Lanreotide 30 mg and Lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during Lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during Lanreotide Autogel treatment. In conclusion, this clinical study shows that Lanreotide Autogel is at least as efficacious and well tolerated as Lanreotide 30 mg. This new long-acting Lanreotide formulation, Lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.
Philippe Caron - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness and tolerability of 3 year Lanreotide autogel treatment in patients with acromegaly
Clinical Endocrinology, 2006Co-Authors: Philippe Caron, M. Cogne, Isabelle Raingeard, Veronique Bexbachellerie, Jean Marc KuhnAbstract:OBJECTIVE During short-term treatment, monthly subcutaneous injections of Lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of Lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS Fourteen patients (nine females, five males) were treated with titrated doses of Lanreotide Autogel. DESIGN This clinical study was an extension of a previous trial. After three fixed-dose Lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of Lanreotide Autogel. MEASUREMENTS Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of Lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of Lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GH
-
Effectiveness and tolerability of 3‐year Lanreotide Autogel® treatment in patients with acromegaly
Clinical endocrinology, 2006Co-Authors: Philippe Caron, M. Cogne, Isabelle Raingeard, Véronique Bex‐bachellerie, Jean Marc KuhnAbstract:OBJECTIVE During short-term treatment, monthly subcutaneous injections of Lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of Lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS Fourteen patients (nine females, five males) were treated with titrated doses of Lanreotide Autogel. DESIGN This clinical study was an extension of a previous trial. After three fixed-dose Lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of Lanreotide Autogel. MEASUREMENTS Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of Lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of Lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GH
-
Comparison of octreotide acetate LAR and Lanreotide SR in patients with acromegaly.
Clinical endocrinology, 2000Co-Authors: Philippe Chanson, Philippe Caron, V Boerlin, Christiane Ajzenberg, Y. Bachelot, Pedro J. Benito, J Bringer, B. Charbonnel, C. Cortet, Brigitte DelemerAbstract:BACKGROUND AND OBJECTIVE The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues. Long-acting depot formulations for intramuscular injection of two somatostatin analogues have recently become available: octreotide acetate LAR (Sandostatin® LAR®, Novartis Pharma AG) and Lanreotide SR (Somatuline®, Ipsen Biotech). We wished to compare efficacy of octreotide LAR and Lanreotide SR in acromegalic patients. PATIENTS AND METHODS A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied. Before the study, all patients had been treated with intramuscular injections of Lanreotide SR (mean duration, 26 months) at a dose of 30 mg which was injected every 10 days in 64 and every 14 days in 61 patients, respectively. All patients were switched from Lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months. In order to obtain efficacy and safety data of Lanreotide SR under study conditions, it was decided to randomly assign at day 1, in a 3 : 1 ratio, the time point of the treatment switch; 27 of the patients were randomly assigned to continue the Lanreotide SR treatment for the first 3 months of the study (group A); they were on octreotide LAR 20 mg from month 4–6. The other 98 patients were assigned to be switched to treatment with octreotide LAR 20 mg at day 1 (group B). In group B patients, octreotide LAR treatment was continued until month 6, with an adjustment of the dose based on GH levels obtained at month 3. RESULTS The mean GH concentration decreased from 9.6 ± 1.3 mU/l at the last evaluation on Lanreotide SR to 6.8 ± 1.0 mU/l after three injections of octreotide LAR (P
-
comparison of octreotide acetate lar and Lanreotide sr in patients with acromegaly
Clinical Endocrinology, 2000Co-Authors: Philippe Chanson, Philippe Caron, V Boerlin, Christiane Ajzenberg, Y. Bachelot, Pedro J. Benito, J Bringer, B. Charbonnel, C. Cortet, Brigitte DelemerAbstract:BACKGROUND AND OBJECTIVE The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues. Long-acting depot formulations for intramuscular injection of two somatostatin analogues have recently become available: octreotide acetate LAR (Sandostatin® LAR®, Novartis Pharma AG) and Lanreotide SR (Somatuline®, Ipsen Biotech). We wished to compare efficacy of octreotide LAR and Lanreotide SR in acromegalic patients. PATIENTS AND METHODS A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied. Before the study, all patients had been treated with intramuscular injections of Lanreotide SR (mean duration, 26 months) at a dose of 30 mg which was injected every 10 days in 64 and every 14 days in 61 patients, respectively. All patients were switched from Lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months. In order to obtain efficacy and safety data of Lanreotide SR under study conditions, it was decided to randomly assign at day 1, in a 3 : 1 ratio, the time point of the treatment switch; 27 of the patients were randomly assigned to continue the Lanreotide SR treatment for the first 3 months of the study (group A); they were on octreotide LAR 20 mg from month 4–6. The other 98 patients were assigned to be switched to treatment with octreotide LAR 20 mg at day 1 (group B). In group B patients, octreotide LAR treatment was continued until month 6, with an adjustment of the dose based on GH levels obtained at month 3. RESULTS The mean GH concentration decreased from 9.6 ± 1.3 mU/l at the last evaluation on Lanreotide SR to 6.8 ± 1.0 mU/l after three injections of octreotide LAR (P < 0.001). The percentages of patients with mean GH values ≤ 6.5 mU/l (2.5 μg/l) and ≤ 2.6 mU/l (1.0 μg/l) at the last evaluation on Lanreotide SR were 54% and 14%, and these values increased after 3 months treatment with octreotide LAR to 68% and 35% (P < 0.001), respectively. IGF-I levels were normal in 48% at the last evaluation on Lanreotide SR and in 65% after 3 months on octreotide LAR (P < 0.001). Patients with pre-study pituitary irradiation had lower mean GH and IGF-I concentrations. But the effects of the treatment change did not differ between the irradiated and the nonirradiated patients. In general both drugs were well tolerated. CONCLUSION Octreotide LAR 20 mg administered once monthly was more effective than Lanreotide SR 30 mg administered 2 or 3 times monthly in reducing GH and IGF-I in patients with acromegaly.
Jean Marc Kuhn - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness and tolerability of 3 year Lanreotide autogel treatment in patients with acromegaly
Clinical Endocrinology, 2006Co-Authors: Philippe Caron, M. Cogne, Isabelle Raingeard, Veronique Bexbachellerie, Jean Marc KuhnAbstract:OBJECTIVE During short-term treatment, monthly subcutaneous injections of Lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of Lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS Fourteen patients (nine females, five males) were treated with titrated doses of Lanreotide Autogel. DESIGN This clinical study was an extension of a previous trial. After three fixed-dose Lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of Lanreotide Autogel. MEASUREMENTS Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of Lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of Lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GH
-
Effectiveness and tolerability of 3‐year Lanreotide Autogel® treatment in patients with acromegaly
Clinical endocrinology, 2006Co-Authors: Philippe Caron, M. Cogne, Isabelle Raingeard, Véronique Bex‐bachellerie, Jean Marc KuhnAbstract:OBJECTIVE During short-term treatment, monthly subcutaneous injections of Lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of Lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS Fourteen patients (nine females, five males) were treated with titrated doses of Lanreotide Autogel. DESIGN This clinical study was an extension of a previous trial. After three fixed-dose Lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of Lanreotide Autogel. MEASUREMENTS Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of Lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of Lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GH
Ph. Caron - One of the best experts on this subject based on the ideXlab platform.
-
one year follow up of patients with acromegaly treated with fixed or titrated doses of Lanreotide autogel
Clinical Endocrinology, 2004Co-Authors: Ph. Caron, D. R. Cullen, Jochen Schopohl, Mieke Bex, U Feldtrasmussen, A Pico M Alfonso, S Pynka, Karoly Racz, A Tabarin, Matti VälimäkiAbstract:Summary objective Somatostatin analogue treatment is first-line medical therapy for acromegaly. This study compared the efficacy and tolerability of titrated doses of the long-acting somatostatin analogue preparation Lanreotide Autogel® with fixed doses and with Lanreotide prolonged release (PR) 30 mg microparticles. patients Patients entering the initial study had received a diagnosis of active acromegaly within the previous 5 years. design This open, comparative, multicentre study was a 1-year extension of a previous trial during which patients with acromegaly had switched from Lanreotide PR 30 mg microparticles injected intramuscularly every 7, 10 or 14 days, for at least 3 months, to one of three fixed doses of Lanreotide Autogel® (120, 90, or 60 mg every 28 days, respectively). In this extension study, patients continued to receive 60, 90, or 120 mg of Lanreotide Autogel® by deep subcutaneous injection every 28 days for 1 year. Doses could be titrated at entry or after four or eight injections, according to the GH/IGF-I response (dose increased if GH > 2·5 µg/l, or decreased if GH < 1 µg/l with normal IGF-I). measurements Mean ± SEM GH and IGF-I concentrations were analysed and gallbladder echography performed at weeks 0, 16, 32, and 48. Acromegaly symptoms were recorded monthly and tolerance and side-effects were monitored throughout the study. results In total, 130 patients entered this extension phase. After 1 year of treatment with titrated doses of Lanreotide Autogel®, mean GH (2·4 ± 0·2 µg/l) and IGF-I (287 ± 12 µg/l) concentrations were significantly lower than with Lanreotide microparticles (GH, 2·8 ± 0·2 µg/l, P < 0·001; IGF-I, 332 ± 15 µg/l, P < 0·01) or with fixed-dose Lanreotide Autogel® (GH, 3·0 ± 0·2 µg/l, P < 0·001; IGF-I, 310 ± 14 µg/l, P = 0·02). GH hypersecretion was reduced to ≤ 2·5 µg/l in 68% of patients with titrated-dose Lanreotide Autogel® compared with 49% with microparticles (P < 0·001) and 56% with fixed-dose Lanreotide Autogel® (P ≤ 0·005). In the 65 patients who did not require any dose titration, there was no substantial change in serum Lanreotide concentration, GH or IGF-I levels over the 12-month study duration. Acromegaly was effectively controlled (GH ≤ 2·5 µg/l and normalized IGF-I) in significantly more patients (43%) compared with microparticles (32%; P < 0·05). There was a trend for improved control of acromegalic symptoms with dose titration, whereas the incidence of gastrointestinal symptoms and local tolerance was similar with Lanreotide Autogel® and Lanreotide microparticles. Gallbladder echographies showed new lithiasis in 8% of Lanreotide Autogel® patients. conclusion Dose titration of Lanreotide Autogel® improved GH and IGF-I control in patients with acromegaly beyond that achieved using fixed doses of Lanreotide Autogel® or Lanreotide microparticles. Titrated long-term Lanreotide Autogel® treatment is well tolerated.
-
One-year follow-up of patients with acromegaly treated with fixed or titrated doses of Lanreotide Autogel®
Clinical endocrinology, 2004Co-Authors: Ph. Caron, D. R. Cullen, Jochen Schopohl, Mieke Bex, S Pynka, Karoly Racz, A Tabarin, U Feldt-rasmussen, A M Pico Alfonso, Matti VälimäkiAbstract:Summary objective Somatostatin analogue treatment is first-line medical therapy for acromegaly. This study compared the efficacy and tolerability of titrated doses of the long-acting somatostatin analogue preparation Lanreotide Autogel® with fixed doses and with Lanreotide prolonged release (PR) 30 mg microparticles. patients Patients entering the initial study had received a diagnosis of active acromegaly within the previous 5 years. design This open, comparative, multicentre study was a 1-year extension of a previous trial during which patients with acromegaly had switched from Lanreotide PR 30 mg microparticles injected intramuscularly every 7, 10 or 14 days, for at least 3 months, to one of three fixed doses of Lanreotide Autogel® (120, 90, or 60 mg every 28 days, respectively). In this extension study, patients continued to receive 60, 90, or 120 mg of Lanreotide Autogel® by deep subcutaneous injection every 28 days for 1 year. Doses could be titrated at entry or after four or eight injections, according to the GH/IGF-I response (dose increased if GH > 2·5 µg/l, or decreased if GH
-
Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of Acromegaly
The Journal of clinical endocrinology and metabolism, 2002Co-Authors: Ph. Caron, Albert Beckers, D. R. Cullen, M. I. Goth, B. Gutt, Peter Laurberg, Antonio Picó, Matti Välimäki, W. ZgliczynskiAbstract:Lanreotide Autogel is a new long-acting aqueous preparation of Lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to Lanreotide 30 mg, im (sustained release microparticle formulation). Lanreotide Autogel was administered by deep sc injection every 28 d to 107 patients (54 males and 53 females; mean age, 54 +/- 1.2 yr). All patients had been treated with Lanreotide (30 mg) for at least 3 months before study entry and had a mean GH level less than 10 ng/ml after at least 4 subsequent im injections every 14 d (48%), 10 d (32%), or 7 d (20%). Treatment was switched from Lanreotide 30 mg injected every 14, 10, or 7 d to 60, 90, or 120 mg Lanreotide Autogel, respectively, every 28 d. After three fixed dose injections of Lanreotide Autogel, mean Lanreotide levels were similar to those obtained at steady state with Lanreotide 30 mg. During Lanreotide Autogel treatment, the control of acromegalic symptoms was comparable with that previously achieved during Lanreotide 30 mg treatment. After 3 injections of Lanreotide Autogel, mean GH (2.87 +/- 0.22 ng/ml) and IGF-I (317 +/- 15 ng/ml) values were comparable with those recorded at the end of Lanreotide 30 mg treatment (GH, 2.82 +/- 0.19 ng/ml; IGF-I, 323 +/- 16 ng/ml). GH levels below 2.5 ng/ml and age-/sex-normalized IGF-I were achieved in 33% and 39% of patients during Lanreotide 30 mg and Lanreotide Autogel treatment, respectively. Diarrhea, abdominal pain, and nausea were reported by 38%, 22%, and 18% of patients during Lanreotide 30 mg treatment and by 29%, 17%, and 9% of patients, respectively, during Lanreotide Autogel treatment. In conclusion, this clinical study shows that Lanreotide Autogel is at least as efficacious and well tolerated as Lanreotide 30 mg. This new long-acting Lanreotide formulation, Lanreotide Autogel, which is administered from a small volume, prefilled syringe by deep sc injection, is therefore likely to improve the acceptability of medical treatment for patients requiring long-term somatostatin analog therapy.
-
Somatuline(R) Autogel(R), a new formulation of Lanreotide for the treatment of acromegalic patients
Annales d'endocrinologie, 2002Co-Authors: Ph. CaronAbstract:Lanreotide Autogel((R)) is a new long-acting aqueous preparation of Lanreotide for the treatment of acromegaly, and is administered by deep sc injection from small-volume pre-filled syringes. The aim of this study was to evaluate the efficacy and safety of this new long-acting formulation in a large population of acromegalic patients previously responsive to im Lanreotide 30mg (sustained release microparticle formulation). Lanreotide Autogel((R)) was administered by deep sc injection every 28 days to 107 patients (54 males, 53 females; mean age 54+/-1.2 years). All patients had been treated with Lanreotide 30mg for at least 3 months before study entry, and had a mean GH level
Massimo Giusti - One of the best experts on this subject based on the ideXlab platform.
-
Slow-release Lanreotide and octreotide LAR in the medical therapy of acromegaly
European journal of endocrinology, 2000Co-Authors: Massimo Giusti, P. Sessarego, Graziano Timossi, Liliana BoccaAbstract:The first line of treatment for active acromegaly is still neurosurgery followed by radiotherapy. Octreotide (1), slow-release (SR) Lanreotide (2) and octreotide LAR (3) are currently administered before surgery or in patients in whom surgery and/or radiotherapy have failed to restore normal growth hormone (GH)/insulin-like growth factor-I (IGF-I) levels. Cozzi et al. (4) have recently shown that octreotide LAR, a somatostatin analogue to be administered at 28-day intervals, seems to be more efficacious than SR Lanreotide, a somatostatin analogue administered at intervals ranging from 10 to 14 days. This observation seems quite surprising, as previous studies comparing effectiveness and tolerability of the different somatostatin analogue formulations did not show significant differences. Colao et al. (5) observed that SR Lanreotide treatment in 45 patients seemed to be just as efficacious as octreotide and to cause a similar incidence of side effects. In the European multicentre study, Lancranjan et al. (3) reported that monthly intramuscular administration of octreotide was at least as effective, well tolerated and safe as octreotide therapy of three daily subcutaneous injections. In a preliminary study, we did not observe significant differences in GH/IGF-I control in 5 patients who were switched from SR Lanreotide to octreotide LAR (6). In Cozzi’s paper (4), 12 acromegalic patients (6 men and 6 women; aged 28–76 years) with active disease on chronic SR Lanreotide (injections every 7–21 days) treatment (6–24 months) were switched directly to treatment with octreotide LAR (10–30 mg). Data collected on stabilised SR Lanreotide treatment were compared after 3 and 6 months of octreotide LAR therapy. Cozzi et al. (4) reported normal GH levels (
-
Effectiveness and tolerability of slow release Lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group
The Journal of clinical endocrinology and metabolism, 1996Co-Authors: Massimo Giusti, G Gussoni, C.m. Cuttica, G. GiordanoAbstract:The objective of the study was to determine the tolerability and effectiveness of the slow release (SR) somatostatin analog Lanreotide in active acromegaly. Fifty-seven patients, unselected in terms of their previous responsiveness to octreotide therapy, were included in a prospective, open label study carried out at 6 Italian endocrinological centers. The effects of 6 months of SR Lanreotide, given at first every 14 days at a dosage of 30 mg, im, were recorded. In some patients (33%), drug dosage was adjusted by increasing the dose (to 60 mg, im) and/or shortening the time interval (every 10 days) of SR Lanreotide administration. Fifty patients completed the 6-month period of therapy; 2 subjects dropped out because of adverse events, and 5 dropped out because of ineffectiveness after changes in drug administration. The first SR Lanreotide injection produced more than 50% suppression of GH levels from the basal value in 93% of patients. Thirteen days later, baseline GH levels were reduced by over 50% in 2...
